AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients
- Date 3 Sep 2021
Enhertu demonstrates transformative progression-free survival in HER2-positive metastatic breast cancer; data in lung and gastric cancers show strong efficacy across HER2-targetable tumours.
Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settings
AstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021.
You might also be interested in these articles
Steaming up Success: ARU student’s path from café to creativity
We recently did a Q&A session with Anglia Ruskin student Soorya Jith, who started his journey as a Barista at the Lakeside Café within the Bradfield Centre on Cambridge Science Park. He has now transitioned to Krank, also located on the Park, as a Junior Graphic Designer.
Sun 21 Apr 2024
Cambridge Science Park
Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors
Leading DeepTech Venture-Builder Further Strengthens its Unique Position to Cultivate Innovative Technologies with the Addition of Seasoned Industry Professionals
Sun 14 Apr 2024
Cambridge Future Tech
Xampla welcomes former P&G chemist to team as scale-up accelerates
accelerates CREATOR of plastic-free, natural materials, Xampla, continues to scale-up the commercialisation of its biodegradable Morro materials with new industry hire.
Fri 1 Mar 2024
Xampla Ltd
